Abrisqueta Pau
Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Departament de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
J Clin Med. 2024 Mar 27;13(7):1929. doi: 10.3390/jcm13071929.
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of lymphoma, comprising heterogeneous patient subgroups with distinctive biological and clinical characteristics. The R-CHOP combination (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard initial treatment, yielding prolonged remissions in over 60% of patients with advanced-stage disease. Several attempts to enhance the outcomes of this regimen over the last two decades have shown limited success. Various novel therapeutic approaches have recently emerged in lymphoma, demonstrating promising results. These include small molecules, novel monoclonal antibodies, antibody-drug conjugates (ADC), bispecific antibodies (BsAbs), and chimeric antigen receptor (CAR) T-cell therapy. This review explores recent advancements in therapeutic strategies for DLBCL and their potential impact on the initial management of DLBCL patients.
弥漫性大B细胞淋巴瘤（DLBCL）是淋巴瘤最常见的亚型，由具有独特生物学和临床特征的异质性患者亚组组成。R-CHOP联合方案（利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松）一直是标准的初始治疗方案，使超过60%的晚期疾病患者获得长期缓解。在过去二十年中，为提高该方案疗效所做的几次尝试成效有限。最近淋巴瘤领域出现了各种新型治疗方法，并显示出有前景的结果。这些方法包括小分子、新型单克隆抗体、抗体药物偶联物（ADC）、双特异性抗体（BsAb）和嵌合抗原受体（CAR）T细胞疗法。本综述探讨了DLBCL治疗策略的最新进展及其对DLBCL患者初始管理的潜在影响。
